Alopecia areata is not contagious. You cannot catch it from someone else or spread it through touching, sharing hats, or any other form of contact. It is an autoimmune condition, meaning the body’s own immune system mistakenly attacks its hair follicles. About 2% of the global population is affected, and the hair loss has nothing to do with bacteria, viruses, or fungi.
Why It’s Not Contagious
Contagious conditions require an infectious agent, something that can pass from one person to another. Alopecia areata has no infectious agent. The hair loss happens because a specific type of immune cell, called a CD8+ T cell, targets the hair follicle as though it were a foreign invader. These immune cells cluster around the base of the follicle in a pattern pathologists describe as a “swarm of bees,” forcing the hair into a resting phase and preventing new growth from starting.
Under normal conditions, hair follicles maintain a kind of immune shield that keeps them hidden from the immune system. In alopecia areata, that shield breaks down. Once exposed, proteins in the follicle trigger an inflammatory response that sustains the hair loss. This is an internal malfunction, not an infection, so there is nothing to transmit to another person.
How It Differs From Contagious Hair Loss
The condition most commonly confused with alopecia areata is tinea capitis, a fungal scalp infection (ringworm) that genuinely is contagious and spreads through direct contact or shared items like combs and towels. Both conditions can cause round patches of hair loss, which is why the confusion exists. But there are visible differences. Tinea capitis causes flaking and scaling on the scalp, while alopecia areata leaves smooth, bare skin with no scaling at all. Alopecia areata also produces distinctive “exclamation mark” hairs, short broken strands that taper as they approach the scalp, which ringworm does not.
If you’re unsure which type of hair loss you’re seeing, those two clues (scaling versus smooth skin) are the fastest way to tell them apart before seeing a dermatologist.
What Actually Causes It
The exact trigger remains unclear, but genetics play a meaningful role. About 17.6% of people with alopecia areata have a family member with the same condition. That family clustering suggests inherited genes create susceptibility, though having a relative with it doesn’t guarantee you’ll develop it. Environmental factors likely act as triggers in people who are already genetically predisposed.
People with alopecia areata are also more likely to have other autoimmune or immune-related conditions. Nearly 19% of patients in one large study had thyroid disease, compared to about 8% in a control group. Eczema was about four times more common, and vitamin D deficiency affected 39% of patients versus 13% of controls. Anemia and iron deficiency also showed up more frequently. These overlapping conditions reinforce that alopecia areata is a systemic immune issue, not something caused by outside exposure.
Types and Severity
Alopecia areata exists on a spectrum. The most common form, patchy alopecia areata, produces one or more coin-sized bald spots on the scalp or body. Alopecia totalis involves losing all or nearly all scalp hair. Alopecia universalis, the rarest form, means complete or near-complete loss of hair everywhere on the body, including eyebrows, eyelashes, and body hair.
The condition can also affect nails. Between 20% and 30% of people with alopecia areata develop nail changes like pitting, brittleness, ridges, roughness, or small white spots. These nail changes sometimes appear before any noticeable hair loss, and they’re more common in people with the universalis form.
Regrowth and Treatment
Hair may regrow on its own within about a year, particularly when the hair loss is limited to a few patches. Some people experience a single episode and never lose hair again. Others have recurring bouts or progress to more extensive forms.
For severe cases, a newer class of medications called JAK inhibitors has changed the treatment landscape. These drugs work by blocking the specific signaling pathway that drives the immune attack on hair follicles. Three JAK inhibitors are now FDA-approved for severe alopecia areata: baricitinib (approved in 2022), ritlecitinib (approved in 2023 for ages 12 and up), and deuruxolitinib. In clinical trials, roughly 30% to 42% of patients on these medications achieved significant hair regrowth within a year, compared to about 1% on placebo. These are oral medications taken daily, and hair loss can return if the medication is stopped.
For milder cases, dermatologists often use other approaches like steroid injections into the affected patches or topical treatments to calm the local immune response. The right approach depends on how much hair has been lost and how long it’s been going on.